Comparison of the pathological response to 2 or 4 cycles of neoadjuvant CAPOX in II/III rectal cancer patients with low/intermediate risks: study protocol for a prospective, non-inferior, randomized control trial (COPEC trial)

Peer Review reports

Original Submission
12 Nov 2022	Submitted	Original manuscript
16 Dec 2022	Reviewed	Reviewer Report - Kirsty Loudon
9 Feb 2023	Reviewed	Reviewer Report - Jinbo Yue
20 May 2023	Author responded	Author comments - Yu Shen
Resubmission - Version 2
20 May 2023	Submitted	Manuscript version 2
Publishing
23 May 2023	Editorially accepted
13 Jun 2023	Article published	10.1186/s13063-023-07405-x

Back to article page